Amalgamated Bank raised its holdings in shares of Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,586 shares of the semiconductor company’s stock after buying an additional 6,300 shares during the quarter. Amalgamated Bank’s holdings in Synopsys were worth $19,531,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Norges Bank acquired a new stake in Synopsys in the 2nd quarter worth $647,964,000. Ameriprise Financial Inc. grew its position in Synopsys by 29.1% during the second quarter. Ameriprise Financial Inc. now owns 2,598,874 shares of the semiconductor company’s stock worth $1,333,095,000 after buying an additional 585,494 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Synopsys by 177.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 865,987 shares of the semiconductor company’s stock valued at $427,269,000 after acquiring an additional 553,924 shares during the period. Ninety One UK Ltd acquired a new position in Synopsys in the 3rd quarter valued at approximately $249,851,000. Finally, Aspex Management HK Ltd lifted its position in shares of Synopsys by 106.0% in the 2nd quarter. Aspex Management HK Ltd now owns 645,895 shares of the semiconductor company’s stock worth $331,137,000 after acquiring an additional 332,364 shares during the period. Institutional investors and hedge funds own 85.47% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have recently issued reports on SNPS. Needham & Company LLC boosted their price objective on Synopsys from $550.00 to $580.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Piper Sandler lowered shares of Synopsys from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $602.00 to $520.00 in a report on Tuesday. Wells Fargo & Company increased their price objective on shares of Synopsys from $445.00 to $500.00 and gave the company an “equal weight” rating in a research note on Thursday, December 11th. Morgan Stanley lifted their target price on shares of Synopsys from $510.00 to $550.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Finally, Bank of America raised shares of Synopsys from an “underperform” rating to a “neutral” rating and lowered their target price for the company from $525.00 to $500.00 in a research note on Monday, December 8th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $553.57.
Insider Transactions at Synopsys
In related news, insider Janet Lee sold 250 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $530.00, for a total value of $132,500.00. Following the transaction, the insider directly owned 11,959 shares of the company’s stock, valued at approximately $6,338,270. The trade was a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shelagh Glaser sold 3,657 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $460.77, for a total transaction of $1,685,035.89. Following the sale, the chief financial officer directly owned 17,842 shares of the company’s stock, valued at approximately $8,221,058.34. This trade represents a 17.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 4,157 shares of company stock worth $1,945,036. Insiders own 0.62% of the company’s stock.
Synopsys Price Performance
NASDAQ SNPS opened at $516.31 on Friday. The company has a 50-day moving average price of $455.35 and a 200-day moving average price of $504.95. Synopsys, Inc. has a 52 week low of $365.74 and a 52 week high of $651.73. The company has a quick ratio of 1.52, a current ratio of 1.62 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $98.78 billion, a P/E ratio of 64.62, a PEG ratio of 4.30 and a beta of 1.12.
Synopsys (NASDAQ:SNPS – Get Free Report) last issued its quarterly earnings results on Wednesday, December 10th. The semiconductor company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.11. The business had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.25 billion. Synopsys had a net margin of 18.89% and a return on equity of 7.89%. The company’s revenue for the quarter was up 37.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.40 earnings per share. Synopsys has set its FY 2026 guidance at 14.320-14.400 EPS and its Q1 2026 guidance at 3.520-3.580 EPS. Equities research analysts anticipate that Synopsys, Inc. will post 10.64 earnings per share for the current year.
Synopsys Company Profile
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
Featured Articles
- Five stocks we like better than Synopsys
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- URGENT: Trump Just Triggered AI’s Biggest Disruption Yet
- Wall Street Alert: Buy AES
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
